"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial"
Trends in Molecular Medicine , 28(7), 542-556
However, if you have any underlying medical conditions or are taking medications, we recommend consulting your healthcare professional before use
Close monitoring for disordered eating patterns is essential, especially in adolescents who may be vulnerable to unhealthy weight control behaviors
The BCBS FEP may also cover alternative or complementary therapies depending on medical necessity and the recommendation of a Texas healthcare provider
376 patients previously treated with the injectable GLP-1s semaglutide and tirzepatide for 72 weeks were transferred onto orforglipron (Foundayo) pills or a placebo for a year Those whod previously been on tirzepatide kept off 75% of the weight theyd lost compared with 49% in the placebo group, and those whod been on semaglutide kept off 79% of the weight compared with 38% in the placebo group Orforglipron (Foundayo) is the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions It was a randomised, double-blind and placebo-controlled study
%20(1).png)
